Back to today’s briefing

Story perspectives

February 2025: Growth Stocks Thrive Amid Favorable Conditions

2/2/2025

24 6

Summary

Story summary

February 2025 highlights growth stocks such as Accolade Inc., Akero Therapeutics, and Eli Lilly with notable 30-day returns.
Favorable economic conditions benefit established firms, especially in health tech and AI sectors.
Investors should prioritize metrics like EPS growth and revenue history for stock selection.
Long-term investment strategies are advisable, acknowledging potential volatility in growth stocks.

History

Historical Context

February 2025's growth in health tech and AI stocks echoes the late 1990s tech boom. Then, low oil prices and technological advances fueled rapid economic expansion. Today, similar favorable conditions drive investment in innovative sectors, highlighting a cyclical pattern of economic optimism and volatility.

1 of 2

Story summary

February 2025 highlights growth stocks such as Accolade Inc., Akero Therapeutics, and Eli Lilly with notable 30-day returns.
Favorable economic conditions benefit established firms, especially in health tech and AI sectors.
Investors should prioritize metrics like EPS growth and revenue history for stock selection.
Long-term investment strategies are advisable, acknowledging potential volatility in growth stocks.

1 / 2